



MITHRA SIGNS A LICENSE AND SUPPLY AGREEMENT WITH GEDEON RICHTER FOR ITS PRODUCT TIBELIA® IN 6 EUROPEAN TERRITORIES

Liège, Belgium 28 June 2016 – Mithra announces that it signed a non-exclusive License and Supply Agreement with the Hungarian company Gedeon Richter for its product Tibelia®. Under the terms of this contract, Mithra grants Gedeon a non-exclusive license for the commercialization of Tibelia® in Italy, Switzerland, Spain, Germany, Belgium and Luxembourg.

Altogether, these markets represent more than 45 million tablets, accounting for a total market of about EUR 18,5 million¹.

This contract follows the one signed with Mercury in April, covering the commercialisation of Tibelia® in the United Kingdom, the fourth biggest potential of the global tibolone market (14 million tablets).

François Fornieri, CEO of Mithra Pharmaceuticals, comments: *“This contract confirms that Tibelia® is definitely able to provide Mithra with a source of near-term cash flow in terms of license payments and sales revenue. We expect new contracts in the next few months”.*

A source of cash flow and a greater presence on an interesting worldwide market

The first indication which Tibelia® targets is the treatment of oestrogen deficiency symptoms in postmenopausal women, more than one year after menopause. A second indication is prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.

These indications represent an interesting and growing market of 131 million euro, showing a growth in value of 4.7%. In terms of volume, this means 311 million tablets, growing at a rate of 1.9%².

¹ Source : IMS 2015 Audited SU Volume

² Source : IMS 2015 Audited SU Volume

About Tibelia®

Tibelia® is a synthetic steroid (tibolone) intended to be used for hormone replacement therapy. Tibelia® is a bioequivalent of Livial® 2.5mg which is a product that mimics the activity of the female sex hormones in the body, and is used especially for the relief of symptoms occurring after menopause. In some countries, this product is also used for the prevention of osteoporosis. It has been demonstrated that tibolone has favourable effects on various tissues in the body, such as brain, vagina and bone.³

About Gedeon Richter

Headquartered in Hungary, Gedeon Richter Plc. is an innovation-driven specialty pharmaceutical company. Vertically integrated, the company is engaged in pharmaceutical manufacturing, research and development, sales and marketing. Richter markets its products in more than 100 countries worldwide, through its own marketing network.

Pictures

For pictures of François Fornieri, please click here on the following link:

<http://www.mithra.com/en/logo/>

For more information, please contact:

Press

Julie Dessart

Chief Communication Officer

+32 4 349 28 22

+32 475 86 41 75

press@mithra.com

Investor Relations

François Fornieri, CEO

+32 4 349 28 22

investorrelations@mithra.com

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women's Health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs

³ Livial® Patient Information Leaflet.

and complex therapeutical entities in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com